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Introduction {#s1}
============

Kawasaki disease (KD) is a systemic vasculitis which was first reported by Dr. Kawasaki in 1974 in English from Japan [@pone.0105236-Kawasaki1]. It mainly affects children less than 5-years-old world widely, especially in Asia. Japan, Korea and Taiwan have the highest incidence of KD worldwide from 66-234/100,000 children less than 5 years old [@pone.0105236-Huang1], [@pone.0105236-Wang1], [@pone.0105236-Nakamura1]. The clinical characteristics and diagnosis criteria of KD include a prolonged fever (more than 5 days), bilateral non-purulent conjunctivitis, diffuse mucosal inflammation of oral cavity with strawberry tongue and fissure lips, polymorphous skin rashes over body surface, indurative angioedema of the hands and feet followed by desquamation in the sub-acute stage, and lymphadenopathy over neck [@pone.0105236-Wang1], [@pone.0105236-Newburger1]. Fever for more than 5 days with 4 of the 5 diagnostic criteria matches the diagnosis of KD [@pone.0105236-Kuo1]. The most common sequel of KD is coronary artery lesions (CAL) formation [@pone.0105236-Liang1], [@pone.0105236-Burns1]. KD has become the most common cause of acquired heart disease in children of developed countries. The cause of KD is still unclear. Both genetic and environmental factors are considered to be important factors of KD. High dose intravenous immunoglobulin (IVIG) with aspirin is considered to be an effective treatment for KD [@pone.0105236-Burns1]. The pharmacological mechanism of IVIG also remains unclear. The potential mechanisms of IVIG action include modulation of cytokine production, suppression of antibody synthesis and immune regulation [@pone.0105236-Burns1]. IVIG therapy itself has greatly decreased the rate of aneurysms; however, some patients are unresponsive to the initial IVIG treatment. The incidence rate of IVIG resistance varies from 9.4--23% between countries [@pone.0105236-Kuo1].

IVIG is used to treat a wide range of autoimmune or immune related diseases. The immunosuppressive effects of IVIG are, in part, attributed to terminal α2,6-linked sialic acid residues on the N-linked glycans of the IgG Fc (fragment crystallizable) domain. α2,6-linked sialylated IgG was reported to interact with dendritic cell-specific intercellular adhesion molecule-3 grabbing non-integrin (*DC-SIGN, CD209*), and trigger an anti-inflammatory cascade that promotes the up regulation of inhibitory FcγRs on macrophages [@pone.0105236-Anthony1]. CD209 is a dendritic cell (DC)-specific C-type lectin superfamily receptor that has functions of pattern recognition receptor in the innate response to infection, DC migration, and the initial steps of T cell activation [@pone.0105236-Zhou1]. Several lines of evidence indicated the association between CD209 and infectious diseases, such as dengue fever, tuberculosis and AIDS [@pone.0105236-Marzi1], [@pone.0105236-Vannberg1], [@pone.0105236-Koizumi1], [@pone.0105236-Sarkar1]. Thus, CD209 may be important in the anti-inflammatory functions of IVIG. Yu et al. showed CD209 (rs4804803) promoter variants have effects on susceptibility to KD, but not IVIG treatment response (15). Portman et al. revealed that Asians with the major allele "A" in rs2287886 of CD209 were more likely to be IVIG non-responders, but this allele is a minor allele in Hispanic and Caucasian ethnic groups [@pone.0105236-Yu1], [@pone.0105236-Portman1]. In this study, we hypothesized that CD209 may be involved in the susceptibility to KD, CAL formation and IVIG treatment response in KD patients.

Materials and Methods {#s2}
=====================

Subjects {#s2a}
--------

All KD patients were children who fulfilled the diagnostic criteria for KD and were admitted between 2000 and 2012 as described in our previous studies [@pone.0105236-Liang1], [@pone.0105236-Kuo2], [@pone.0105236-Kuo3], [@pone.0105236-Yu2]. This study was approved by the Institutional Review Board of Chang Gung Memorial Hospital (97-0029B). The IRB approved this consent procedure. Blood samples were collected after written informed consent was obtained from parents or guardians. The participant consent was recorded by decode method. We excluded patients who did not meet the diagnostic criteria for KD. CAL was defined as the internal diameter of the coronary artery greater than 3 mm (4 mm, if the subject was more than 5 year-old) or the internal diameter of a segment being at least 1.5 times than adjacent segment by echocardiogram [@pone.0105236-Shulman1], [@pone.0105236-Kuo4], [@pone.0105236-Kuo5]. IVIG responsiveness was defined as fever subside 48 hours after the completion of IVIG treatment and no fever (temperature, \>38°C) recurrence for at least 7 days with marked improvement of inflammatory signs [@pone.0105236-Kuo3], [@pone.0105236-Kuo6]. A total of 567 control subjects (without any history of Kawasaki disease) were recruited from patients of outpatient department who volunteered to participate in our study while receiving an allergen test and with a negative allergen test result.

DNA extraction {#s2b}
--------------

DNA was extracted by treating 0.5% SDS lysis buffer, and then adding protease K (1 mg/ml) for digestion of nuclear protein for 4 h at 60°C. After using Gentra extraction kit and followed by 70% alcohol precipitation, the total DNA was harvested.

Genotyping {#s2c}
----------

Utilizing the Han Chinese in Beijing as a reference population sample from the haplotype map database (<http://www.hapmap.org>), we selected the nine tagging SNPs of *CD209* (rs8112310, rs4804800, rs11465421, rs1544766, rs4804801, rs2287886, rs735239, rs735240, and rs4804804) with a minimum allele frequency of greater than 1% in the Beijing Han Chinese population. There are 4 SNPs (rs4804800, rs11465421, rs1544766, rs4804801) located on 3′ UTR, and 5 SNPs (rs8112310, rs2287886, rs735239, rs735240, rs4804804) near 5′ UTR. Genotyping was performed by using TaqMan Allelic Discrimination assay, and the polymerase chain reaction (PCR) was accomplished by using ABI StepOnePlus Thermal Cycler. Followed up in PCR, the fluorescence was detected and analyzed through the System SDS software version 2.2.2.

Statistical analysis {#s2d}
--------------------

All statistical analysis was performed by using JMP 9.0 for windows. The genotypes and allele frequencies associated with the susceptibility of KD and disease outcomes (CAL and IVIG treatment response) were analysis by χ^2^ test. Hardy-Weinberg equilibrium was also performed by the χ^2^ test with 1 degree of freedom. Linkage disequilibrium (LD) was assessed for haplotype blocks were defined using the default setting of the Haploview software 4.1.

Results {#s3}
=======

Association between *CD209* polymorphisms and susceptibility of Kawasaki disease {#s3a}
--------------------------------------------------------------------------------

A total of 948 subjects (381 cases and 567 controls) were recruited in this study. The basal characteristics of KD patients and control subjects are shown in [Table 1](#pone-0105236-t001){ref-type="table"}. Of the 381 KD patients, 126 (33.1%) patients had coronary artery lesion (CAL), and 49 (12.9%) patients suffered from persistent fever after they treated with IVIG. As shown in [Table 2](#pone-0105236-t002){ref-type="table"}, Three SNPs (rs4804800, rs2287886, and rs735240) of *CD209* showed significance with regards to susceptibility of KD. The GG genotype of SNP rs4804800 had 1.60-fold increased risk compared with AG and AA genotypes of KD (*P* = 0.0336, OR (95% CI)  = 1.60 (1.04--2.46)). The variants of rs2287886 and rs735240 revealed protective effects, the GG genotype of rs2287886 and AA genotype of rs735240 were associated with a lower risk of KD ([Table 2](#pone-0105236-t002){ref-type="table"}). However, all significances disappeared if we performed Bonfferoni correction (*P*\<0.0055).

10.1371/journal.pone.0105236.t001

###### Basal characteristics of patients with Kawasaki disease and normal controls.

![](pone.0105236.t001){#pone-0105236-t001-1}

  Characteristics          Patients with KD   Normal Control
  ----------------------- ------------------ ----------------
  Male gender, No. (%)       247 (66.8%)       314 (56.2%)
  Mean (SD) age (years)        1.7±1.6           5.7±4.9
  Age range (years)             0--11             0--51
  CAL formation              126 (33.1%)     
  IVIG resistance             49 (12.9%)     

CAL: coronary artery lesions; IVIG: intravenous immunoglobulin; SD: standard deviation.

10.1371/journal.pone.0105236.t002

###### Genotype and allele frequencies of the *CD209* gene in controls and patients with Kawasaki disease.

![](pone.0105236.t002){#pone-0105236-t002-2}

                Genotype   Case (%) (n = 381)   Control (%) (n = 567)    MAF    *P* Value[a](#nt103){ref-type="table-fn"}   OR (95% CI)[b](#nt104){ref-type="table-fn"}   
  ------------ ---------- -------------------- ----------------------- ------- ------------------------------------------- ---------------------------------------------- -----------------------
  rs8112310        AA          51 (13.7)              66 (12.2)         0.361                     0.359                                        0.5292                        1.13 (0.77--1.68)
                   AT          168 (44.9)            256 (47.4)                                                                                                           
                   TT          155 (41.4)            218 (40.4)                                                                                                           
  rs4804800        GG          46 (12.8)              45 (8.4)          0.336                     0.309                     **0.0336** [\*](#nt102){ref-type="table-fn"}   **1.60 (1.04--2.46)**
                   AG          149 (41.5)            240 (45.0)                                                                                                           
                   AA          164 (45.7)            249 (46.6)                                                                                                           
  rs11465421       TT           19 (5.4)              26 (6.0)          0.248                     0.260                                        0.7292                        0.90 (0.49--1.65)
                   GT          136 (38.8)            174 (40.1)                                                                                                           
                   GG          196 (55.8)            234 (53.9)                                                                                                           
  rs1544766        GG           33 (8.8)              37 (6.7)          0.294                     0.279                                        0.2404                        1.34 (0.82--2.18)
                   AG          154 (41.2)            232 (42.3)                                                                                                           
                   AA          187 (50.0)            280 (51.0)                                                                                                           
  rs4804801        AA          54 (15.2)              65 (14.6)         0.399                     0.386                                        0.8011                        1.05 (0.71--1.56)
                   AT          175 (49.3)            214 (48.0)                                                                                                           
                   TT          126 (35.5)            167 (37.4)                                                                                                           
  rs2287886        GG           22(6.0)               56 (10.9)         0.296                     0.338                       0.0118[\*](#nt102){ref-type="table-fn"}        0.52 (0.32--0.87)
                   AG          174(47.3)             237 (45.9)                                                                                                           
                   AA          172(46.7)             223 (43.2)                                                                                                           
  rs735239         GG           9 (2.7)               10 (3.0)          0.160                     0.193                                        0.8421                        0.91 (0.37--2.27)
                   AG          86 (26.4)             108 (32.6)                                                                                                           
                   AA          231 (70.9)            213 (64.4)                                                                                                           
  rs735240         AA           14 (3.9)              37 (7.3)          0.215                     0.265                       0.0337[\*](#nt102){ref-type="table-fn"}        0.51 (0.27--0.95)
                   AG          128 (35.2)            195 (38.4)                                                                                                           
                   GG          221 (60.9)            276 (54.3)                                                                                                           
  rs4804804        AA          77 (22.9)              87 (20.7)         0.476                     0.429                                        0.4550                        0.80 (0.56--1.14)
                   AG          166 (49.4)            187 (44.4)                                                                                                           
                   GG          93 (27.7)             147 (34.9)                                                                                                           

\*Significant (*P*\<0.05) values are in bold.

*P* values are calculated using the Pearson\'s x^2^ test for the recessive model.

ORs are for the recessive model (minor allele homozygotes versus heterozygotes and major allele homozygotes).

*CD209* polymorphisms had no association with CAL and IVIG treatment responsiveness {#s3b}
-----------------------------------------------------------------------------------

The related complications and IVIG treatment responses of KD were also examined in this study. Thus, we tested the relationship between *CD209* genetic polymorphisms and CAL formation. As shown in [Table 3](#pone-0105236-t003){ref-type="table"}, none of *CD209* polymorphisms significantly associated with CAL formation. In addition, we didn\'t find any association between the genetic variants of *CD209* and the outcomes of IVIG treatment ([Table 4](#pone-0105236-t004){ref-type="table"}).

10.1371/journal.pone.0105236.t003

###### Genotype and allele frequencies of *CD209* gene in patients having Kawasaki disease with or without coronary artery lesion formation.

![](pone.0105236.t003){#pone-0105236-t003-3}

                Genotype   CAL (%) (n = 126)   Without (%) (n = 252)    MAF    *P* Value[a](#nt106){ref-type="table-fn"}   OR (95% CI)[b](#nt107){ref-type="table-fn"}  
  ------------ ---------- ------------------- ----------------------- ------- ------------------------------------------- --------------------------------------------- -------------------
  rs8112310        AA          16 (13.0)             35 (14.1)         0.341                     0.371                                       0.7711                      0.91 (0.48--1.72)
                   AT          52 (42.3)            114 (46.0)                                                                                                          
                   TT          55 (44.7)             99 (39.9)                                                                                                          
  rs4804800        GG          15 (12.6)             31 (13.1)         0.315                     0.346                                       0.8997                      0.96 (0.50--1.85)
                   AG          45 (37.8)            102 (43.0)                                                                                                          
                   AA          59 (49.6)            104 (43.9)                                                                                                          
  rs11465421       TT           4 (3.4)              15 (6.6)          0.252                     0.247                                       0.2142                      0.50 (0.16--1.50)
                   GT          52 (43.7)             83 (36.2)                                                                                                          
                   GG          63 (52.9)            131 (57.2)                                                                                                          
  rs1544766        GG          10 (8.1)              23 (9.3)          0.285                     0.298                                       0.7155                      0.87 (0.40--1.88)
                   AG          50 (40.7)            102 (41.1)                                                                                                          
                   AA          63 (51.2)            123 (49.6)                                                                                                          
  rs4804801        AA          16 (13.8)             37 (15.7)         0.371                     0.411                                       0.6421                      0.86 (0.46--1.62)
                   AT          54 (46.5)            120 (50.8)                                                                                                          
                   TT          46 (39.7)             79 (33.5)                                                                                                          
  rs2287886        GG           4 (3.3)              18 (7.4)          0.314                     0.287                                       0.1239                      0.43 (0.15--1.26)
                   AG          68 (56.2)            104 (42.6)                                                                                                          
                   AA          49 (40.5)            122 (50.0)                                                                                                          
  rs735239         GG           2 (1.9)               7 (3.2)          0.175                     0.151                                       0.4962                      0.58 (0.12--2.79)
                   AG          33 (31.1)             52 (23.7)                                                                                                          
                   AA          71 (67.0)            159 (72.9)                                                                                                          
  rs735240         AA          2 (1.67)              12 (5.0)          0.217                     0.213                                       0.1230                      0.32 (0.08--1.36)
                   AG          48 (40.0)             78 (32.5)                                                                                                          
                   GG          70 (58.3)            150 (62.5)                                                                                                          
  rs4804804        AA          24 (22.6)             53 (23.2)         0.500                     0.469                                       0.9029                      0.97 (0.56--1.67)
                   AG          58 (54.8)            108 (47.4)                                                                                                          
                   GG          24 (22.6)             67 (29.4)                                                                                                          

\*Significant (*P*\<0.05) values are in bold.

*P* values are calculated using the Pearson\'s x^2^ test for the recessive model.

ORs are for the recessive model (minor allele homozygotes versus heterozygotes and major allele homozygotes).

10.1371/journal.pone.0105236.t004

###### Genotype and allele frequencies of the *CD209*gene in patients with Kawasaki disease responding or not responding to intravenous immunoglobulin treatment.

![](pone.0105236.t004){#pone-0105236-t004-4}

                Genotype   Resistant (%) (n = 49)   Responsive (%) (n = 326)    MAF    *P* Value[a](#nt109){ref-type="table-fn"}   OR (95% CI)[b](#nt110){ref-type="table-fn"}  
  ------------ ---------- ------------------------ -------------------------- ------- ------------------------------------------- --------------------------------------------- -------------------
  rs8112310        AA             9 (18.4)                 41 (12.9)           0.418                     0.351                                       0.2942                      1.53 (0.69--3.36)
                   AT            23 (46.9)                 142 (44.5)                                                                                                           
                   TT            17 (34.7)                 136 (42.6)                                                                                                           
  rs4804800        GG             7 (15.6)                 38 (12.3)           0.367                     0.330                                       0.5455                      1.31 (0.55--3.13)
                   AG            19 (42.2)                 127 (41.2)                                                                                                           
                   AA            19 (42.2)                 143 (46.4)                                                                                                           
  rs11465421       TT             1 (2.2)                   18 (6.0)           0.189                     0.259                                       0.3020                      0.36 (0.05--2.52)
                   GT            15 (33.3)                 120 (39.9)                                                                                                           
                   GG            29 (64.4)                 163 (54.1)                                                                                                           
  rs1544766        GG             5 (10.4)                  27 (8.4)           0.323                     0.289                                       0.6500                      1.26 (0.46--3.45)
                   AG            21 (43.8)                 131 (40.9)                                                                                                           
                   AA            22 (45.8)                 162 (50.6)                                                                                                           
  rs4804801        AA            11 (23.9)                 42 (13.8)           0.457                     0.389                                       0.0733                      1.97 (0.94--4.13)
                   AT            20 (43.5)                 153 (50.1)                                                                                                           
                   TT            15 (32.6)                 110 (36.1)                                                                                                           
  rs2287886        GG             3 (6.2)                   19 (6.0)           0.271                     0.299                                       0.9571                      1.04 (0.29--3.64)
                   AG            20 (41.7)                 150 (47.8)                                                                                                           
                   AA            25 (52.1)                 145 (46.2)                                                                                                           
  rs735239         GG             2 (4.7)                   7 (2.5)            0.131                     0.163                                       0.4016                      1.08 (0.23--4.96)
                   AG             7 (16.7)                 78 (27.6)                                                                                                            
                   AA            33 (78.6)                 197 (69.9)                                                                                                           
  rs735240         AA             2 (4.2)                   12 (3.9)           0.177                     0.218                                       0.9251                      1.08 (0.23--4.96)
                   AG            13 (27.1)                 111 (35.9)                                                                                                           
                   GG            33 (68.7)                 186 (60.2)                                                                                                           
  rs4804804        AA            13 (29.5)                 63 (21.8)           0.511                     0.472                                       0.2541                      1.50 (0.75--3.03)
                   AG            19 (43.2)                 147 (50.9)                                                                                                           
                   GG            12 (27.3)                 79 (27.3)                                                                                                            

\*Significant (*P*\<0.05) values are in bold.

*P* values are calculated using the Pearson\'s x^2^ test for the recessive model.

ORs are for the recessive model (minor allele homozygotes versus heterozygotes and major allele homozygotes).

*CD209* haplotypes associated with Kawasaki disease susceptibility {#s3c}
------------------------------------------------------------------

We further calculated pairwise linkage disequilibrium (LD) ([Fig. 1](#pone-0105236-g001){ref-type="fig"}) and analyzed haplotypes of *CD209*. The *CD209* haplotype rs8112310/rs4804800/rs11465421/rs1544766 (Block 1) had no significant association with KD susceptibility ([Table 5](#pone-0105236-t005){ref-type="table"}). However, rs2287886/rs735239/rs735240 (Block 2) pairwise allele analysis showed that A/A/G haplotype (*P* = 0.0002, OR (95% CI) = 1.61 (1.25--2.08)) and G/A/G haplotype (*P* = 0.0365, OR (95% CI) = 1.52 (1.03--2.26)) had a higher risk of KD when compared with G/G/A haplotype ([Table 6](#pone-0105236-t006){ref-type="table"}).

![CD209 gene linkage disequilibrium and haplotype block structure in KD.\
The number on the cell is the LOD score of D′.](pone.0105236.g001){#pone-0105236-g001}

10.1371/journal.pone.0105236.t005

###### Haplotype frequencies of the *CD209* gene in controls and patients with Kawasaki disease.

![](pone.0105236.t005){#pone-0105236-t005-5}

  rs8112310/rs4804800/rs11465421/rs1544766    Case (%) (n = 381)   Control (%) (n = 567)      OR (95% CI)      *P* Value
  ------------------------------------------ -------------------- ----------------------- ------------------- -----------
  A/G/G/G                                         184 (25.7)            211 (21.4)         1.23 (0.94--1.62)    0.1295
  A/G/G/A                                          29 (4.1)              38 (3.9)          1.08 (0.64--1.82)    0.7690
  T/G/G/G                                          12 (1.7)              15 (1.5)          1.13 (0.52--2.48)    0.7542
  T/A/G/G                                          7 (1.0)               13 (1.3)          0.76 (0.30--1.95)    0.5701
  A/A/G/A                                          35 (4.9)              57 (5.8)          0.87 (0.55--1.38)    0.5524
  T/A/G/A                                         256 (35.8)            380 (38.5)         0.95 (0.75--1.22)    0.7081
  T/A/T/A                                         185 (25.9)            262 (26.6)             Reference      

Haplotype frequency less than 1% was excluded.

10.1371/journal.pone.0105236.t006

###### Haplotype frequencies of the *CD209* gene in controls and patients with Kawasaki disease.

![](pone.0105236.t006){#pone-0105236-t006-6}

  rs2287886/rs735239/rs735240    Case (%) (n = 381)   Control (%) (n = 567)      OR (95% CI)                      *P* Value
  ----------------------------- -------------------- ----------------------- ------------------- -------------------------------------------
  A/A/G                              468 (67.2)            521 (59.5)         1.61 (1.25--2.08)   0.0002[\*\*](#nt113){ref-type="table-fn"}
  A/A/A                               10 (1.4)              13 (1.5)          1.38 (0.59--3.25)                    0.4543
  G/A/G                               66 (9.5)              78 (8.9)          1.52 (1.03--2.26)    0.0365[\*](#nt114){ref-type="table-fn"}
  G/A/A                               27 (3.9)              36 (4.1)          1.35 (0.78--2.33)                    0.2809
  G/G/A                              124 (17.8)            223 (25.5)             Reference      

Haplotype frequency less than 1% was excluded.

\*\*Significant (*P*\<0.01) values are in bold.

\*Significant (*P*\<0.05) values are in bold.

Discussion {#s4}
==========

IVIG therapy is used to treat a wide range of autoimmune and immune associated diseases including Kawasaki disease. The treatment effects of IVIG resulted from the terminal α2,6-linked sialic acid residues of the IgG Fc (fragment crystallizable) domain, which were known to be conjugated to the carbohydrate recognition domain (CRD) of the cell-surface lectin. Through this interaction, DC-SIGN and its murine orthologue SIGN-R1 (specific intracellular adhesion molecule-grabbing non-integrin R1) triggered down-stream expression of immunosuppressive cytokines and receptors. Consistent with this model, the anti-inflammatory effect of IVIG treatment is abolished in a murine knock-out of *SIGN-R1* and can be restored by a knock-in with human *CD209* [@pone.0105236-Yu3].

CD209 is a transmembrane lectin receptor on dendritic cells with multiple immune modulation function [@pone.0105236-Gringhuis1]. *CD209* can recognize many pathogens, such as viruses (HIV-1, dengue, and measles virus) [@pone.0105236-Geijtenbeek1], [@pone.0105236-Pokidysheva1], [@pone.0105236-deWitte1], bacteria (*Helicobacter pylori*, *Mycobacterium tuberculosis*) [@pone.0105236-Gringhuis2], and fungi (*Candida albicans* and *Aspergillus fumigatus*) [@pone.0105236-Cambi1] contributing to the generation of pathogen-tailored immune responses and immunosuppressive responses by the MAPK pathway in DCs [@pone.0105236-Mittal1]. The pathogen which causes KD still remains unknown. The hypothesis that [@pone.0105236-Lidar1] is that risk of KD results from an undefined infectious process in a genetically predisposed individual with a "double hit model" (32). The genetic predisposition is suggested based on clinical and epidemiologic features [@pone.0105236-Burns1], [@pone.0105236-Nakamura2]. Immune related genes including *ITPKC, CD40, BLK and FcγR2A* were reported as important genetic predisposition of KD [@pone.0105236-Onouchi1], [@pone.0105236-Onouchi2], [@pone.0105236-Lee1], [@pone.0105236-Khor1].

The polymorphism of *CD209* has been previously reported as an important factor of KD susceptibility [@pone.0105236-Yu1]. Portman\'s study also showed a significant association between CD209 polymorphisms and IVIG treatment in the Asian group (N = 64 vs. 12, responsiveness vs. non-responsiveness, respectively, p = 0.04) but not in the Caucasian group (158 vs. 62), Hispanic group (55 vs. 20) and group that pooled of all of the ethnicities (277 vs. 94) [@pone.0105236-Portman1]. In this study, we conducted to investigate 9 tagging SNPs in a Taiwanese population including 332 with IVIG responsiveness and 49 with IVIG non-responsiveness. Our results indicated that CD209 polymorphisms were responsible for the susceptibility of KD, but not IVIG treatment responsiveness. Inconsistences with regards to these results may be due to the limited case numbers, power of statistical test, and different ethnic populations.

In conclusion, our results provided evidence to support the potential role of CD209 in the susceptibility of KD in a Taiwanese population. The roles of genetic polymorphisms of CD209 in inflammatory signaling as well as KD development are still unclear. Functional studies are needed to validate these findings.
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